Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Intangible Assets

Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Intangible Assets · Q1 FY2026 · quarter ended Mar 2026

Intangible assets remains negative

Q1 FY2026 intangible assets was $0, compared with $0 a year earlier.

Context

  • Intangible assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Intangible assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Intangible Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Intangible Assets history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Intangible Assets vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so intangible assets is compared through growth and share of total assets rather than absolute size.
  • Intangible assets amounts to 0.0% of total assets for AVTX, versus a peer median of 0.0%.
AVTX Competitors
Intangible Assets for AVTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ELDNEledon Pharmaceuticals, Inc.Mar 2026$32.39M USD+0.0%+0.0%22.1%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€20.11M EUR——12.1%
XNCRXencor, Inc.Jun 2026$6.52M USD-42.0%-23.2%0.9%
IFRXInflaRx N.V.Mar 2026€45.64K EUR-15.7%-32.8%0.1%
AVTXAvalo Therapeutics, Inc.Mar 2026$0 USD——0.0%
SYRESpyre Therapeutics, Inc.Sep 2026$0 USD——0.0%
ANABAnaptysBio, Inc.Mar 2026$0 USD——0.0%
ACRSAclaris Therapeutics, Inc.Mar 2026$0 USD——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 USD——0.0%
IMUXImmunic, Inc.Mar 2026$0 USD——0.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —-15.7%-23.2%0.0%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.59M13.17M7.42M134.55M15.86M
Short-term Investments000082.48M
Net Receivables4.8M1.92M136K611K0
Inventory38K20K000
Other Current Assets51K1.31M844K3.73M6.95M
Total Current Assets61.85M16.42M8.4M138.89M105.29M
Property, Plant & Equipment (Net)2.7M2.41M1.97M1.21M460K
Goodwill14.41M14.41M10.5M10.5M10.5M
Intangible Assets38K0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.23M131K131K131K210K
Total Non-current Assets18.37M16.95M12.6M11.84M11.17M
Total Assets80.21M33.37M20.99M150.73M116.46M
Account Payables3.37M2.88M446K283K137K
Short-term Debt05.93M000
Tax Payables00000
Deferred Revenue088K000
Other Current Liabilities4.32M3.18M3.06M3.24M12.41M
Total Current Liabilities19.89M22.11M4.62M6.96M12.94M
Long-term Debt32.83M13.49M002M
Deferred Tax Liabilities113K141K155K270K434K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities4.3M8.54M8.92M10.47M18M
Total Non-current Liabilities37.24M22.17M9.07M10.74M20.47M
Total Liabilities57.13M44.28M13.69M17.7M33.41M
Common Stock9K01K10K18K
Retained Earnings(262.17M)(303.82M)(335.13M)(370.26M)(448.52M)
Accumulated OCI000068K
Other Stockholders Equity00000
Minority Interest00000
Total Equity23.08M(10.92M)7.3M133.03M83.05M
Total Debt33.32M19.95M537K568K2.43M
Net Debt(21.27M)6.78M(6.88M)(133.98M)(13.43M)

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.